Does TARLATAMAB Cause Therapy partial responder? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Therapy partial responder have been filed in association with TARLATAMAB. This represents 4.8% of all adverse event reports for TARLATAMAB.
7
Reports of Therapy partial responder with TARLATAMAB
4.8%
of all TARLATAMAB reports
4
Deaths
3
Hospitalizations
How Dangerous Is Therapy partial responder From TARLATAMAB?
Of the 7 reports, 4 (57.1%) resulted in death, 3 (42.9%) required hospitalization.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TARLATAMAB. However, 7 reports have been filed with the FAERS database.
What Other Side Effects Does TARLATAMAB Cause?
Cytokine release syndrome (59)
Death (31)
Immune effector cell-associated neurotoxicity syndrome (30)
Off label use (14)
Disease progression (11)
Small cell lung cancer (10)
Metastases to central nervous system (7)
Pyrexia (6)
Dysgeusia (5)
Hypotension (5)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which TARLATAMAB Alternatives Have Lower Therapy partial responder Risk?
TARLATAMAB vs TARLATAMAB-DLLE
TARLATAMAB vs TASIGNA
TARLATAMAB vs TASIMELTEON
TARLATAMAB vs TAVABOROLE
TARLATAMAB vs TAXOL